LEO Pharma US

Company snapshot

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. For more

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for LEO Pharma US. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for LEO Pharma US.

1. Jun 8, 2026 Clinical update

   LP0162-2328 — Approved

2. Jun 8, 2026 Clinical update

   LP0189-2318 — Phase 1

3. Jun 8, 2026 Clinical update

   LP0162-1336 — Phase 3

4. Jun 8, 2026 Clinical update

   LP0160-1329 — Approved

5. Jun 8, 2026 Clinical update

   Adtralza 150 mg solution for injection in pre-filled syringe — Phase 2

View all clinical trial activity →

• What is LEO Pharma US?

  LEO Pharma A/S is a pharma organization headquartered in Ballerup, DK. Primary therapeutic focus areas include Psoriasis Vulgaris, Moderate-to-severe plaque psoriasis and a body weight ≥120 kg., Mild to severe palmoplantar pustulosis, Atopic dermatitis and moderate-to severe atop

• Is LEO Pharma US publicly traded?

  LEO Pharma US appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does LEO Pharma US develop or market?

  We link 11 drug profile(s) where LEO Pharma US is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/leo-pharma-a-s#company-drugs.

• What are the latest developments for LEO Pharma US?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does LEO Pharma US focus on?

  LEO Pharma US focuses on Psoriasis Vulgaris, Moderate-to-severe plaque psoriasis and a body weight ≥120 kg., Mild to severe palmoplantar pustulosis based on our analysis of their pipeline programs and drug development activities.